{"id":"W4389480834","doi":"10.1016/j.iotech.2023.100668","title":"157TiP Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Ipsen; Sanofi; Bayer HealthCare; F. Hoffmann-La Roche; Incyte; Natera; Amgen; ViiV Healthcare; Eisai; AstraZeneca; Bristol-Myers Squibb","keywords":"Pemetrexed; Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Oncology; KRAS; Internal medicine; Lung; Cancer; Cisplatin; Colorectal cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001041958,0.001400051,0.00178757,0.0003771193,0.0003170282,0.001175698,0.0009753337,0.001246397,0.004860419],"category_scores_gemma":[0.0004590752,0.0006787213,0.001497765,0.0003579932,0.0008002971,0.0007273642,0.0003242559,0.003469133,0.001540091],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009821375,"about_ca_system_score_gemma":0.001976928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001276402,"about_ca_topic_score_gemma":0.004040854,"domain_scores_codex":[0.9997366,0.00008736388,0.0000153528,0.00005407779,0.00003672056,0.00006988169],"domain_scores_gemma":[0.9995834,0.00004023442,0.00005204934,0.00003026281,0.00003173927,0.0002623186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6662543,0.1402676,0.005258711,0.001987862,0.002012314,0.0003352848,0.0002835061,0.002296743,0.07074726,0.0005945044,0.00661542,0.1033465],"study_design_scores_gemma":[0.4926857,0.4890209,0.00694213,0.00006661181,0.0006270421,0.0003375127,0.00009207529,0.0008942548,0.004434805,0.0002063494,0.004655788,0.00003688377],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873446,0.003123881,0.0004270047,0.0004845362,0.0002315751,0.003486193,0.001576387,0.000146311,0.003179542],"genre_scores_gemma":[0.9771873,0.004539249,0.001856678,0.001494213,0.0002166537,0.003331796,0.005585755,0.00005141151,0.005736835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004860419,"threshold_uncertainty_score":0.01625979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01084802645926599,"score_gpt":0.3612404445660097,"score_spread":0.3503924181067438,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}